James B. Yu

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Sarah B. Goldberg, Scott Gettinger, Amit Mahajan et al. · The Lancet Oncology · 2016 · 996 citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

Sarah B. Goldberg, Kurt A. Schalper, Scott Gettinger et al. · The Lancet Oncology · 2020 · 538 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis

William J. Magnuson, N.H. Lester-Coll, Abraham J. Wu et al. · Journal of Clinical Oncology · 2017 · 461 citations

Medicine, Oncology, Radiation Oncology +17

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

Jonathan Knisely, James B. Yu, Jaclyn C. Flanigan et al. · Journal of neurosurgery · 2012 · 333 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Extended Survival and Prognostic Factors for Patients With <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis

Kimberly L. Johung, Norman Yeh, Neil Desai et al. · Journal of Clinical Oncology · 2015 · 331 citations · Full text

Medicine, Oncology, Radiation Oncology +17